IPP Bureau
PM chairs high-level meeting to asses situation of Covid-19 & Influenza
By IPP Bureau - March 23, 2023
PM emphasises the need to enhance lab surveillance & testing of all Severe Acute Respiratory Illness (SARI) cases & ramp up genome sequencing
PM to address One World TB Summit tomorrow
By IPP Bureau - March 23, 2023
PM to launch TB-Mukt Panchayat initiative; official pan-India rollout of a shorter TB Preventive Treatment and Family-centric care model for TB
Emmes acquires Essex Management
By IPP Bureau - March 23, 2023
Essex enriches and complements Emmes’ services
Medanta launches women and child care services in Gurugram
By IPP Bureau - March 23, 2023
Women of all ages will get round-the-clock access to comprehensive treatment
Investment in healthcare workforce key to accelerating India’s economic growth: Experts
By IPP Bureau - March 23, 2023
Integration of modern and traditional medicine to facilitate the illness to wellness journey
OPPI launches ‘Bharat Ke Liye’ to reinforce commitment to improve health outcomes
By IPP Bureau - March 23, 2023
This initiative encapsulates the essence of OPPI’s commitment towards enabling a healthier India
FedEx Express to showcase healthcare solutions at Indian Biologics Festival 2023
By IPP Bureau - March 23, 2023
FedEx will be displaying a wide-range of effective healthcare packaging and specialized tracking technology
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
By IPP Bureau - March 23, 2023
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
Zydus receives final and tentative approval from USFDA for Tofacitinib Tablets
By IPP Bureau - March 22, 2023
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
Granules Consumer Health concludes FDA audit with zero observations
By IPP Bureau - March 22, 2023
The audit is a pre-approval inspection for three products filed from the facility
Lupin receives approval from USFDA for Brexpiprazole Tablets
By IPP Bureau - March 22, 2023
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Zydus granted Orphan Drug Designation by USFDA for ZYIL1
By IPP Bureau - March 22, 2023
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
CTSI appoints Harish Trivedi as CEO, South Asia
By IPP Bureau - March 22, 2023
PHARMAP 2023 to focus on pharmaceutical challenges and strategies
By IPP Bureau - March 22, 2023
The Congress gathers the whole value chain of the pharmaceutical industry on June, 12-13, 2023 in Switzerland
Glenmark receives ANDA approval for Prochlorperazine Maleate Tablets
By IPP Bureau - March 21, 2023
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
